AccuStem Sciences, Inc.
ACUT
$0.55
$0.000.00%
| Weiss Ratings | ACUT - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Very Weak | |||
| Risk Grade | E+ | |||
| Reward Grade | E | |||
| Rating Factors | ACUT - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Very Weak | |||
| Total Return Index | Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | ACUT - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 0.19 | |||
| Price History | ACUT - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | 19.57% | |||
| 30-Day Total Return | 129.17% | |||
| 60-Day Total Return | 19.57% | |||
| 90-Day Total Return | 77.42% | |||
| Year to Date Total Return | 22.77% | |||
| 1-Year Total Return | 44.74% | |||
| 2-Year Total Return | -44.81% | |||
| 3-Year Total Return | -60.71% | |||
| 5-Year Total Return | -- | |||
| 52-Week High % Change | -17.91% | |||
| 52-Week Low % Change | 154.75% | |||
| Price | ACUT - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $0.67 | |||
| 52-Week Low Price | $0.22 | |||
| 52-Week Low Price (Date) | Dec 31, 2024 | |||
| 52-Week High Price (Date) | Jul 31, 2024 | |||
| Valuation | ACUT - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 6.24M | |||
| Enterprise Value | 6.26M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -0.12 | |||
| Earnings Per Share Growth | -50.45% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | -- | |||
| Price/Book (Q) | -1.95 | |||
| Enterprise Value/Revenue (TTM) | -- | |||
| Price | $0.55 | |||
| Enterprise Value/EBITDA (TTM) | -4.55 | |||
| Enterprise Value/EBIT | -4.54 | |||
| Market Cap Category | Nano Cap | |||
| Dividends and Shares | ACUT - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 11.35M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | ACUT - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | -- | |||
| Address | 5 Penn Plaza New York, NY 10001 | |||
| Website | accustem.com | |||
| Country | United States | |||
| Year Founded | 2013 | |||
| Profitability | ACUT - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -- | |||
| Profit Margin | -- | |||
| Management Effectiveness | ACUT - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -476.96% | |||
| Return on Equity | -- | |||
| Income Statement | ACUT - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | -- | |||
| Total Revenue (TTM) | -- | |||
| Revenue Per Share | -- | |||
| Gross Profit (TTM) | -- | |||
| EBITDA (TTM) | -1.38M | |||
| EBIT (TTM) | -1.38M | |||
| Net Income (TTM) | -1.38M | |||
| Net Income Avl. to Common (TTM) | -1.38M | |||
| Total Revenue Growth (Q YOY) | -- | |||
| Earnings Growth (Q YOY) | 45.16% | |||
| EPS Diluted (TTM) | -0.12 | |||
| EPS Diluted Growth (Q YOY) | 45.16% | |||
| Balance Sheet | ACUT - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 37.10K | |||
| Cash Per Share (Q) | $0.00 | |||
| Total Current Assets (Q) | 102.50K | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | -3.19M | |||
| Current Ratio (Q) | 0.031 | |||
| Book Value Per Share (Q) | -$0.28 | |||
| Total Assets (Q) | 103.80K | |||
| Total Current Liabilities (Q) | 3.30M | |||
| Total Debt (Q) | 57.60K | |||
| Total Liabilities (Q) | 3.30M | |||
| Total Common Equity (Q) | -3.19M | |||
| Cash Flow | ACUT - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -- | |||
| Cash from Financing (TTM) | 925.60K | |||
| Net Change in Cash (TTM) | -33.90K | |||
| Levered Free Cash Flow (TTM) | 638.30K | |||
| Cash from Operations (TTM) | -959.50K | |||
